Clinical efficacy and safety of Xuanfei Touxie Fang as a complementary medicine in the treatment of SARS-CoV-2 Omicron variant: A retrospective study

Abstract

Introduction: To explore the clinical efficacy and safety of Xuanfei Touxie Fang (XFTXF) as a complementary medicine in the treatment of SARS-CoV-2 Omicron variant. Methods: A retrospective study of 317 patients with ordinary symptoms admitted to our hospital from December 2022 to February 2023 were divided into the observation group (n = 224) and the control group (n = 93). The observation group was treated with Xuanfei Touxie Fang combined with conventional treatment and the control group treated with conventional treatment alone. Recovery time of symptoms, length of hospital stay, clinical cure rate and recovery rate of chest CT manifestations were compared between the two groups. Results: The time to recover from fever (median: 1 vs 3 days) and the length of hospital stay (median: 7 vs 9 days) of the observation group after treatment were significantly shorter than the control group. The difference was statistically significant (P 0.05). Discussion: Numerous studies have demonstrated that Xuanfei Touxie Fang, which is frequently used in respiratory diseases, has anti-coronavirus effects by inhibiting viral replication, release, penetration, and RNA synthesis. Therefore, we treated COVID-19 with it and evaluated its safety and effectiveness. Conclusions: Xuanfei Touxie Fang as a complementary medicine has a significant effect in the treatment of COVID-19, which can reduce the duration of fever and the length of hospital stay, improve the clinical cure rate and recovery rate of chest CT manifestations.

Keywords

• Xuanfei Touxie Fang
• Omicron variant
• COVID-19
• Complementary medicine